HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Clinical Phenotype of CNGA3-Related Achromatopsia: Pretreatment Characterization in Preparation of a Gene Replacement Therapy Trial.

AbstractPurpose:
The purpose of this study was to clinically characterize patients with CNGA3-linked achromatopsia (CNGA3-ACHM) in preparation of a gene therapy trial.
Methods:
Thirty-six patients (age 7-56 years) with complete (cACHM) or incomplete (iACHM) CNGA3-ACHM were examined, including detailed psychophysical tests, extended electrophysiology, and assessment of morphology by fundus autofluorescence and spectral-domain optical coherence tomography (SD-OCT).
Results:
Mean best-corrected visual acuity was 0.78 ± 0.14 logMAR. Color vision tests were consistent with a rod-dominated function in every cACHM patient. Microperimetry indicated an overall lowered retinal sensitivity within 20° of visual field. In electroretinography (ERG), photopic responses were nondetectable in cACHM patients, but residual cone responses were observed in the iACHM patients. Scotopic responses were altered referring to anomalies of photoreceptor and postreceptor signaling, whereas in voltage versus intensity functions, Vmax was significantly below normal values (P < 0.05). In contrast, slope (n) and semisaturation intensity (K) were found to be within normal limits. Spectral-domain OCT examination showed no specific changes in 14.7%, disruption of the ellipsoid zone (EZ) at the fovea in 38.2%, absent EZ in 17.7%, a hyporeflective zone in 20.5%, and outer retinal atrophy in 8.9% of all cases and foveal hypoplasia in 29 patients (85%). No correlation of retinal morphology with visual function or with a specific genotype was found. The severity of morphologic and functional changes lacked a robust association with age.
Conclusions:
Our extended investigations prove that even among such a genetically homogenous group of patients, no specific correlations regarding function and morphology severity and age can be observed. Therefore, the therapeutic window seems to be wider than previously indicated.
AuthorsDitta Zobor, Annette Werner, Franco Stanzial, Francesco Benedicenti, Günther Rudolph, Ulrich Kellner, Christian Hamel, Sten Andréasson, Gergely Zobor, Torsten Strasser, Bernd Wissinger, Susanne Kohl, Eberhart Zrenner, RD-CURE Consortium
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 58 Issue 2 Pg. 821-832 (02 01 2017) ISSN: 1552-5783 [Electronic] United States
PMID28159970 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CNGA3 protein, human
  • Cyclic Nucleotide-Gated Cation Channels
Topics
  • Adolescent
  • Adult
  • Child
  • Color Perception (physiology)
  • Color Vision Defects (genetics, pathology, physiopathology, therapy)
  • Cyclic Nucleotide-Gated Cation Channels (genetics)
  • Dark Adaptation (physiology)
  • Electroretinography
  • Female
  • Genetic Therapy
  • Humans
  • Male
  • Middle Aged
  • Phenotype
  • Prospective Studies
  • Psychophysics
  • Retina (pathology, physiopathology)
  • Sensory Thresholds
  • Tomography, Optical Coherence
  • Visual Acuity (physiology)
  • Visual Fields (physiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: